旗濱集團(601636.SH):以所持湖南藥玻全部股權共設福建藥玻 將成為公司在醫藥玻璃材料產業佈局、研發和對外投資的戰略平台
格隆匯 11 月 25日丨旗濱集團(601636.SH)公佈,湖南旗濱醫藥材料科技有限公司(“湖南藥玻”)的全部股東,以所持其全部股權作價出資新設福建旗濱醫藥材料科技有限公司(“福建藥玻”),福建藥玻註冊資本1億元,此次交易不涉及現金投資,不涉及股權投資比例變化。此次交易後,湖南藥玻原各股東成為福建藥玻的股東,湖南藥玻成為新公司福建藥玻的全資子公司。福建藥玻作為公司的控股子公司,將成為公司在醫藥玻璃材料產業佈局、研發和對外投資(含公司對紹興藥玻項目的投資)的戰略平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.